FDA-approved Digestive & weight

Lutetium Lu-177 dotatate

Lutetium Lu-177 dotatate is a SSTR-targeted radiopeptide. It is filed in this library under digestive & weight, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Lutetium Lu-177 dotatate has an FDA-approved product on the U.S. market, marketed as Lutathera under application NDA208700.

The current label is held by Advanced Accelerator Applications USA, Inc.

From the FDA label

What Lutetium Lu-177 dotatate is approved to treat

is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Lutetium Lu-177 dotatate, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on digestive & weight

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Lutetium Lu-177 dotatate. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides